Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.

Bonnet, P O; Yoon, B S; Wong, W-Y; Boswell, K; Ewenstein, B M

Bonnet, P O; Yoon, B S; Wong, W-Y; Boswell, K; Ewenstein, B M.

Affiliation

Bonnet PO; Medical Outcomes Research and Economics, Baxter BioScience, One Baxter Way, Westlake Village, CA, USA.

Haemophilia ; 15(5): 1083-9, 2009 Sep.

Article in En | MEDLINE | ID: mdl-19456876

Subject(s)

Autoantibodies/administration & dosage; Blood Coagulation Factors/administration & dosage; Factor VIIa/administration & dosage; Hemophilia A/drug therapy; Hemostatics/administration & dosage; Orthopedics/methods; Autoantibodies/economics; Blood Coagulation Factors/economics; Cost-Benefit Analysis; Drug Administration Schedule; Factor VIIa/economics; Health Care Costs; Hemophilia A/economics; Hemostatics/economics; Humans; Models, Economic; Orthopedics/economics; Postoperative Hemorrhage/drug therapy; Postoperative Hemorrhage/economics; Recombinant Proteins/administration & dosage; Recombinant Proteins/economics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Orthopedics / Autoantibodies / Blood Coagulation Factors / Hemostatics / Factor VIIa / Hemophilia A Type of study: Evaluation_studies / Health_economic_evaluation / Prognostic_studies Limits: Humans Language: En Journal: Haemophilia Journal subject: HEMATOLOGIA Year: 2009 Document type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google